Mroz MM, et al. - Focusing on clinical effects of inhaled corticosteroids (ICS) on chronic beryllium disease (CBD), researchers performed this retrospective cohort study, wherein, they noted that ICS treated group showed no improvement in forced vital capacity and diffusion capacity (DLCO), however, no difference in decline was apparent when compared to matched controls. Furthermore, treatment with ICS improved symptoms of dyspnea and cough, particularly in those with obstruction and air trapping. This suggested that these should be considered an indication of ICS use in CBD patients.